Cytora's novel stem cell therapy hOMSC200, derived from human oral mucosa stem cells, demonstrated safety and efficacy in treating chronic diabetic foot ulcers with no immune rejection in a Phase 1/2a trial.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.